> > Centivax

Centivax

Centivax raises $56 million Series A

Centivax, a South San Francisco-based influenza drug trial developer, raised $56 million in a Series A fundraising round led by NFX, Global Health Investment Corporation, and Bill & Melinda Gates Foundation.

Similar Health deals

06/12/2026

Nanordica Medical

Nanordica raises €1.6M fundraising round

Nanordica Medical, a Tallinn-based antibiotic-free wound-care startup,...

06/12/2026

Biodimension

Biodimension raises ₹80 million funding

Biodimension, a Bengaluru-based human tissue models company, raised ₹80...

06/12/2026

Dentroid

Dentroid raises $32M fundraising round

Dentroid, a Canberra, Australia-based needle-free dental technology...

06/12/2026

Avidity Biosciences

Avidity Biosciences acquired for $12B

Avidity Biosciences, a San Diego-based RNA-targeting therapeutics biotech,...

06/12/2026

Firefly Bio

Firefly Bio acquired for $1B

Firefly Bio, a Cambridge, MA-based KRAS inhibitor biotech startup, was...

06/12/2026

Uncovr

Uncovr raises $7M seed round

Uncovr, a New York and Paris-based AI for operative reports, raised $7...

The VC Industry's trusted resource

Stay informed on industry shifts, deal trends, and career opportunities in venture capital.

Get the latest VC moves in your inbox

Jobs

Load more listings

Search for more jobs

Centivax